logo-loader

Creo Medical Group gets "great results" from first upper GI use of Speedboat Inject in Europe

Published: 06:55 28 Jun 2023 EDT

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after the medical device company announced that the first upper gastrointestinal (GI) procedure in Europe has been carried out using the company's Speedboat Inject product.

Gulliford says that the procedure to remove a cancer from a patient's stomach was successfully completed by Adolfo Parra-Blanco at Nottingham University Hospitals, with the "great results... we've come to expect."

Gulliford also explains why Creo is now looking for a new Chairman to help develop the company internationally.

Alvopetro posts 86% net back margin as Q2 volumes jump 26% and Murucututu...

Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) CEO Corey Ruttan tells Proactive's Stephen Gunnion that Q2 2026 sales volumes averaged 3,067 barrels of oil equivalent per day, up 26% year-on-year, with revenue of just over $19 million and funds flow from operations of $14.1...

23 hours, 2 minutes ago